Literature DB >> 19406472

Bispecific immunotoxins.

Arthur E Frankel, Jung Hee Woo.   

Abstract

Mesh:

Substances:

Year:  2009        PMID: 19406472     DOI: 10.1016/j.leukres.2009.03.037

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  5 in total

Review 1.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.

Authors:  Liang Shan; Yuanyi Liu; Paul Wang
Journal:  J Basic Clin Med       Date:  2013

Review 3.  Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.

Authors:  Shaowei Zhu; Yuanyi Liu; Paul C Wang; Xinbin Gu; Liang Shan
Journal:  Biomed Res Int       Date:  2017-06-29       Impact factor: 3.411

4.  A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.

Authors:  Xiao-Fang Guo; Xiao-Fei Zhu; Hai-Ying Cao; Gen-Shen Zhong; Liang Li; Bao-Guo Deng; Ping Chen; Pei-Zhen Wang; Qing-Fang Miao; Yong-Su Zhen
Journal:  Oncotarget       Date:  2017-04-18

5.  An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.

Authors:  Xiao-Fang Guo; Xiao-Fei Zhu; Wan-Cai Yang; Sheng-Hua Zhang; Yong-Su Zhen
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.